Business
Financial Results for Third Quarter of FY 2021
Financial Results for Third Quarter of FY 2021.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9139B\n Renalytix AI PLC\n 15 June 2021\n \n \n \n \n Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021\n \n \n \n \n \n \n NEW YORK, June 15, 2021 \n \n - Renalytix AI plc \n (LSE\n : RENX) (NASDAQ: RNLX) (\"Renalytix\" or the \"Company\")\n today\n reported financial results for the quarter and nine months ended March 31, 2021.\n \n \n \n \n \n Recent Highlights\n \n \n · \n Partnership announced with University of Utah health system to improve kidney health and reduce the risk of kidney failure for large-scale populations in the earliest stages of kidney disease. KidneyIntelX to be integrated with the university electronic health records (EHR) system, enabling access to more than 1,700 clinicians.\n \n \n · \n 10 year, government-wide contract granted by the U.S. General Services Administration for KidneyIntelX testing services at $950 per reportable result; applies to more than 140 U.S. government departments, agencies, and affiliates including U.S. Veterans Administration (VA), Department of Defense (DoD) military branches (Army, Navy, Air Force, and Marines), and Indian Health Services (IHS)\n \n \n · \n Data presented at World Congress of Nephrology showing KidneyIntelX accurately predicted progression of diabetic kidney disease (DKD) in a multinational cohort from the CANagliflozin CardioVAScular Assessment Study (CANVAS) with early-stage DKD (stages 1-3). \n \n \n · \n Exclusive option to license novel biomarkers with Joslin Diabetes Center which could provide additional clinical utility for understanding early disease progression, risk of kidney failure, therapeutic response, and the mechanistic pathways of kidney disease beyond the markers that are currently captured by KidneyIntelX.\n \n \n · \n Peer-reviewed data publication demonstrating KidneyIntelX more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care.\n \n \n · \n Partnership announced with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine to implement an advanced clinical care model to improve kidney health and reduce kidney disease progression and kidney failure; KidneyIntelX a...